|
Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care
STATEMENT OF NEED
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kid... |
|
|
Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes
STATEMENT OF NEED
Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusion... |
|
|
Shaping the Future of Myeloma Treatment
To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment plans, based on genomics and risk stratification, to achieve durable remission while minimizing tox... |
|
|
Eradication of Minimal Residual Disease in Multiple Myeloma: The Role and Timing of ASCT
Advances in multiple myeloma (MM) management have equipped oncology health care providers with the tools and strategies for achieving treatment responses in up to 100% of patients, with as many as 80% reaching a complete response (CR). However, achieving a CR does not always predict long-term survival, and most patients ultimately relapse as a result of the persistence of minimal residual disease (MRD) after treatment. MRD cannot be detected with conventional, low-sensitivity evaluation method... |
|
|
Current Obstacles in Myeloma Management: Debating the Evidence
ACTIVITY DESCRIPTION
The clinical multiple myeloma arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The approval of several new agents has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients. Treatment advances have improved median survival; nevertheless, prognosis remains poor for some pat... |
|
|
Osler Radiation Oncology Online Review
The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie... |
|
|
Osler Surgery MOC Online Review
The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie... |
|
|
Nursing Management of Bone Health in Patients With Cancer
STATEMENT OF NEED
Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal complications in patients with cancer and significantly improve quality of life. Combined with preventi... |
|